Literature DB >> 1911195

Whole body hyperthermia and carboplatin: cytotoxicity for murine leukaemia and normal marrow.

E Tapazoglou1, J D Cohen, C L Schmitt, A Khatana, S A Sapareto, H I Robins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1911195      PMCID： PMC1977673          DOI： 10.1038/bjc.1991.343

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  20 in total

1.  Differential effect of hyperthermia on murine bone marrow normal colony-forming units and AKR and L1210 leukemia stem cells.

Authors:  M Flentje; D Flentje; S A Sapareto
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

2.  In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C.

Authors:  B Barlogie; P M Corry; B Drewinko
Journal:  Cancer Res       Date:  1980-04       Impact factor: 12.701

3.  Thymidine enhancement of carboplatin cytotoxicity: in vivo studies in normal B6D2 F1 mice.

Authors:  J D Cohen; H I Robins
Journal:  Cancer Lett       Date:  1990-11-19       Impact factor: 8.679

4.  Adjunctive therapy (whole body hyperthermia versus lonidamine) to total body irradiation for the treatment of favorable B-cell neoplasms: a report of two pilot clinical trials and laboratory investigations.

Authors:  H I Robins; W L Longo; R A Steeves; J D Cohen; C L Schmitt; A J Neville; S O'Keefe; R Lagoni; C Riggs
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-04       Impact factor: 7.038

5.  Thermochemotherapy with cis-platinum, CCNU, BCNU, chlorambucil and melphalan on murine marrow and two tumours: therapeutic gain for melphalan only.

Authors:  D J Honess; N M Bleehen
Journal:  Br J Radiol       Date:  1985-01       Impact factor: 3.039

6.  Potentiation of melphalan by systemic hyperthermia in mice: therapeutic gain for mouse lung microtumours.

Authors:  D J Honess; N M Bleehen
Journal:  Int J Hyperthermia       Date:  1985 Jan-Mar       Impact factor: 3.914

7.  Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

Authors:  A H Calvert; S J Harland; D R Newell; Z H Siddik; A C Jones; T J McElwain; S Raju; E Wiltshaw; I E Smith; J M Baker; M J Peckham; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole-body hyperthermia.

Authors:  H Gerad; M J Egorin; M Whitacre; D A Van Echo; J Aisner
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

9.  Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II).

Authors:  R E Meyn; P M Corry; S E Fletcher; M Demetriades
Journal:  Cancer Res       Date:  1980-04       Impact factor: 12.701

10.  Sensitivity of normal mouse marrow and RIF-1 tumour to hyperthermia combined with cyclophosphamide or BCNU: a lack of therapeutic gain.

Authors:  D J Honess; N M Bleehen
Journal:  Br J Cancer       Date:  1982-08       Impact factor: 7.640
View more
  1 in total

Review 1.  Focal laser treatment in addition to chemotherapy for retinoblastoma.

Authors:  Ido D Fabian; Kenneth P Johnson; Andrew W Stacey; Mandeep S Sagoo; M A Reddy
Journal:  Cochrane Database Syst Rev       Date:  2017-06-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.